Novo Nordisk is working on a new obesity drug that could help ... Semaglutide, the GLP-1 drug that Novo sells under the brand ...

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

The new joint-society guidance may alleviate some of the uncertainty. Among the recommendations: Continuing GLP-1 RAs in the ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

The FDA warns GLP-1 weight loss drug users of aspiration risks during anaesthesia Learn what this update means and how to ...

Losing weight on GLP-1 drugs like Ozempic isn't guaranteed. Experts reveal how to tell if yours isn't working and the next steps you should take to reach your weight loss goals.

For Sprackling, the key to consumers benefiting from GLP-1 medications is responsible use rather than viewing them as a quick ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer new weight loss drugs?